Kisspeptin-10 for Hormone Optimization: Protocol, Dosing, and What to Expect
Evidence strength: moderate
What this protocol is for
Kisspeptin-10 is the upstream signal in the hypothalamic-pituitary-gonadal (HPG) axis. Mechanism: it binds the GPR54 receptor in the hypothalamus and triggers GnRH (gonadotropin-releasing hormone) release, which downstream drives LH and FSH from the pituitary, which downstream drives testosterone production in the testes. For men whose endogenous HPG signaling has degraded (age-related decline, post-cycle recovery, subclinical hypogonadism with preserved testicular function), Kisspeptin-10 restores the upstream signal that the rest of the axis depends on.
The clinical pattern in user reports tracks the mechanism. Men past 40 with declining endogenous testosterone where the issue is upstream signal rather than testicular failure. Users coming off exogenous testosterone or anabolic protocols who need HPG axis recovery support. Fertility-focused protocols where preserved endogenous production matters. Anecdotally, users running Kisspeptin-10 report improved energy and mood within the first 2 to 4 weeks, bloodwork shifts in LH and total testosterone over the cycle, and preserved testicular function on stacks where exogenous androgens would otherwise suppress.
Used by many in the recovery / biohacking space as a precision tool for HPG axis restoration. Run this as a tactical, legal performance layer for hormone optimisation where the upstream signal is the rate-limit. Not appropriate for primary hypogonadism (testicular failure); the upstream signal is irrelevant when the downstream organ cannot respond. Bloodwork before and during the protocol is essential to verify the mechanism is doing what it should.
Dose for hormone optimization
25 to 100 mcg subcutaneous, 1 to 3 times daily. The molecule has a short half-life, which requires multiple daily injections for sustained signal. Common rhythm: 50 mcg twice daily. Some protocols use higher peak dosing (100 mcg) less frequently. Abdominal subcutaneous is the standard route.
Cycle length
4 to 8 weeks per cycle. Post-cycle HPG recovery protocols often run 4 to 6 weeks. Hormone-optimisation cycles run 6 to 8 weeks then reassess with bloodwork. Continuous use beyond 12 weeks is not well characterised; cycling and bloodwork-driven adjustment is the conservative default.
Stack pairings
Commonly stacked with HCG (Human Chorionic Gonadotropin).
Expected timeline
Week 1–2: LH and FSH typically rise in bloodwork (when measured) as the upstream signal restores. Subjective energy and mood improvements often follow. Week 3–4: testosterone levels typically begin to shift; the downstream effect lags the upstream signal by 1 to 2 weeks. Week 4–8: cumulative HPG axis effects build. Bloodwork mid-cycle (week 4) and post-cycle gives the clearest read on protocol effect.
Common mistakes
- Running Kisspeptin-10 for primary hypogonadism. If the testicular tissue cannot respond, the upstream signal is irrelevant. Bloodwork (LH, FSH, testosterone, free testosterone, SHBG) before the protocol identifies whether this is the right tool.
- Skipping bloodwork. The protocol works on the HPG axis; verification of the mechanism requires before-and-after labs. Without bloodwork, the protocol's effect is impossible to assess objectively.
- Treating Kisspeptin-10 as a substitute for TRT. For men with established primary hypogonadism, TRT addresses the deficiency directly. Kisspeptin-10 is for cases where the issue is signal, not capacity.
- Stacking with active TRT without clinical input. Exogenous testosterone suppresses the HPG axis directly; running Kisspeptin-10 against active suppression is contradictory unless the protocol is specifically designed for testicular function preservation under clinical supervision.